2026 VAMA Annual Meeting - Adapting for Change
Tue, Mar 24
|RSM US LLP
The rules of pharmaceutical commercialization have changed. With PBM reform, MFN pricing, the "Pill Penalty" in effect, and unprecedented FDA leadership turnover, “business as usual” is no longer an option. On March 24, learn how to adapt for this change, register now!
Time & Location
Mar 24, 2026, 8:30 AM – 12:00 PM
RSM US LLP, 151 W 42nd St, New York, NY 10036, USA
Guests
About the event
The pharmaceutical market is undergoing its most significant transformation in a generation. With the signing of the sweeping PBM reform, evolving FDA leadership, the evolving "Pill Penalty", and the implementation of Most Favored Nation (MFN) pricing, long‑standing commercial and regulatory strategies are no longer sufficient.
On March 24, 2026, the Value Added Medicines Alliance (VAMA) convenes senior executives and industry leaders in New York City for a focused, half‑day strategy summit built around one imperative: Adapting for Change. This free forum is designed for decision‑makers in the 505(b)(2) and value‑added medicines space who must respond—now—to a rapidly shifting policy and market environment.
The program delivers four expert perspectives shaping commercialization success in 2026:
Regulatory Reality: Navigating FDA leadership turnover and increasingly rigid review expectations.
PBM Disruption & Pricing Strategy: Understanding the downstream impact of the 2026 CAA, MFN pricing as a strategic opportunity, and the "Pill Penalty".